TickerFacts.

UL Solutions Inc. (ULS): Cost of Revenue

Annual figures by period end, from SEC filings.

$1.54B
Year ended 2025-12-31
+5.5%
3-year compound annual growth
2022-12-31: $1.31B2023-12-31: $1.39B2024-12-31: $1.48B2025-12-31: $1.54B$1.54B
2022-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$1.54B+4.4%2026-02-19, From 2025-01-01
2024-12-31$1.48B+6.0%2026-02-19, From 2024-01-01
2023-12-31$1.39B+6.2%2026-02-19, From 2023-01-01
2022-12-31$1.31Bn/a2025-02-20, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Services-Testing Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
UL Solutions Inc. (ULS)2025-12-31$1.54B+4.4%
Incyte Corp (INCY)2025-12-31$372.13M+19.2%
Icon PLC (ICLR)2024-12-31$5.85B+2.2%
NeoGenomics Inc (NEO)2025-12-31$413.04M+11.5%
MaxCyte, Inc. (MXCT)2025-12-31$6.22M-12.4%
20/20 Biolabs, Inc. (AIDX)2025-12-31$1.44M+3.5%
iSpecimen Inc. (ISPC)2025-12-31$1.90M-64.1%
OneMedNet Corp (ONMDW)2025-12-31$1.86M+101.5%
Cannabis Bioscience International Holdings, Inc. (CBIH)2025-05-31$40.1K-12.0%

Compare ULS, INCY, ICLR, NEO side by side · Screen every company in Services-Testing Laboratories ↗